Pharscin Pharma(SZ:002907)2025-06-09 08:58Group 1: Financial Performance - The revenue of the five key traditional Chinese medicine products increased by 21.71% year-on-year in 2024, with 甘桔冰梅片 sales growing by 29.97% and 六味安神胶囊 by 23.38% [2] - In Q1 2025, the revenue of the five key products slightly increased by 0.93%, with 六味安神胶囊 growing by 32.10% and 痛泻宁颗粒 by 80.24% [2] Group 2: Market Strategy - The company focuses on expanding sales in non-grade public hospitals, including grassroots medical institutions, private hospitals, retail chains, and e-commerce platforms [3] - Currently, approximately 70% of sales are from public hospitals, with efforts to increase the share of sales from retail chains and e-commerce platforms [4] Group 3: R&D and Innovation - As of May 2025, the company has integrated with 成都奥睿药业, enhancing its R&D capabilities with 7 innovative drug projects in development targeting various cancers and autoimmune diseases [5] - The lead project, ORIC-1940, is in clinical phase Ia/Ib and aims to be the first innovative drug for secondary hemophagocytic lymphohistiocytosis in China [5] - The company has established a "three-three-three" pipeline structure and has applied for 35 patents, including 17 PCT patents, with 9 granted [6]